<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01517191</url>
  </required_header>
  <id_info>
    <org_study_id>SOS-VE01</org_study_id>
    <nct_id>NCT01517191</nct_id>
  </id_info>
  <brief_title>Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults</brief_title>
  <acronym>SOS-VE01</acronym>
  <official_title>Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Public Health Agency of Canada (PHAC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dalhousie University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This surveillance study will include all consenting adults hospitalized with influenza&#xD;
      (cases) at the SOS network of hospitals as well as influenza negative patients(controls), to&#xD;
      assess vaccine effectiveness in each group. Both groups will be followed throughout their&#xD;
      hospitalization and for 30 days post discharge to monitor severity of illness and outcomes&#xD;
      following their illness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Canadian Immunization Research Network(CIRN) is a collaborative research network which&#xD;
      brings together over 100 investigators in over 40 institutions to evaluate all factors&#xD;
      relevant to the introduction of a pandemic influenza vaccine in Canada. The Serious Outcomes&#xD;
      Surveillance (SOS) Network within CIRN was established in 2009 to plan for evaluation of&#xD;
      influenza vaccine safety and effectiveness. Vaccine effectiveness studies are critical in&#xD;
      assessing vaccine effectiveness under real world conditions and in assessing vaccine&#xD;
      effectiveness in the prevention of severe outcomes. Establishing the methodology and&#xD;
      infrastructure for real-time field assessment of vaccine effectiveness is crucial to inform&#xD;
      policy recommendations for the optimal use of resources, including vaccines.&#xD;
&#xD;
      This study will include all consenting adult patients hospitalized at one of the SOS Network&#xD;
      hospitals during influenza season who test positive for influenza (cases). In addition two&#xD;
      influenza negative controls will be matched to each case to measure differences in vaccine&#xD;
      effectiveness. Specific study aims are:&#xD;
&#xD;
        1. To determine the effectiveness of trivalent influenza vaccination (TIV in general, and&#xD;
           GSK TIV in particular) in preventing influenza-associated hospitalization in adults ≥ 65&#xD;
           years,&#xD;
&#xD;
        2. To determine the effectiveness of influenza vaccination in preventing&#xD;
           influenza-associated death in adults ≥ 65 years&#xD;
&#xD;
        3. To determine the effectiveness of influenza vaccination in preventing&#xD;
           influenza-associated hospitalization and death in adults &lt; 65 years&#xD;
&#xD;
        4. To characterize the burden of disease, clinical outcomes, and resource utilization&#xD;
           associated with influenza A and influenza B lineages&#xD;
&#xD;
        5. To examine clinical and immunologic factors impacting on severity of disease and&#xD;
           influenza vaccine effectiveness in adults&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the burden of influenza disease and influenza vaccine effectiveness.</measure>
    <time_frame>1 Year</time_frame>
    <description>Occurrence of any PCR-confirmed influenza virus infection in vaccinated (&gt;14 days after receipt of seasonal influenza vaccine) or unvaccinated adults ≥ 65 years of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the burden of influenza disease and influenza vaccine effectiveness.</measure>
    <time_frame>1 Year</time_frame>
    <description>Occurrence of any PCR-confirmed influenza virus infection in vaccinated (&gt;14 days after receipt of seasonal influenza vaccine) or unvaccinated adults ≥ 16 years of age</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4197</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza Positive Case</arm_group_label>
    <description>Influenza cases are hospitalized adults who have tested positive for influenza.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza Negative Control</arm_group_label>
    <description>Control Controls are hospitalized adults who have tested negative for influenza.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and Nasopharyngeal swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This observational study is open to adults admitted to hospital with test postitive&#xD;
        influenza or with an influenza like illness who test negative.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients ≥ 16 years of age admitted to participating SOS Network hospitals with&#xD;
             the following admitting diagnoses will be eligible for screening:&#xD;
&#xD;
          -  pneumonia&#xD;
&#xD;
          -  acute exacerbation of chronic obstructive pulmonary disease (AECOPD) or asthma&#xD;
&#xD;
          -  unexplained sepsis&#xD;
&#xD;
          -  Any other respiratory infection or diagnosis Or any respiratory or influenza-like&#xD;
             symptom )(eg dyspnea, cough, sore throat, myalgia, arthralgia, fever, delirium/altered&#xD;
             level of consciousness, CHF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose reason for admission was clearly unrelated to the presence of influenza&#xD;
             (for example, patients admitted due to trauma, elective surgery, or patients who have&#xD;
             an alternative diagnosis that is clearly not respiratory,, e.g. cellulitis,&#xD;
             intra-abdominal process, or gastrointestinal bleeding) Unless being enrolled as a&#xD;
             nosocomial influenza case&#xD;
&#xD;
          -  Patients whose onset of symptoms was prior to or within 72 hours of hospital admission&#xD;
             but who were not tested for influenza within 7 days of hospital admission. These&#xD;
             should be captured on the screening form as screen failures.&#xD;
&#xD;
          -  No children in care will be enrolled in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shelly A McNeil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Science Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Osler Health Center</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Institue of Canada</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto East General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUCH</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUl/CHUQ</name>
      <address>
        <city>Quebec</city>
        <zip>Canada</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Respiratory Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

